Ask AI
Public Law117th CongressHealth
S. 164Became Law

Advancing Education on Biosimilars Act of 2021

This bill became law

Filed
Comm.
Floor
Both
Law

What it doesSummary public law (Apr 23, 2021)

Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

What just happenedApr 23, 2021

Became Public Law No: 117-8.

Who’s behind it

Sen. Hassan, Margaret Wood [D-NH](D-NH)Sponsor
1 cosponsor1 R
Read on Congress.gov
1cosponsors1committees23actions2related bills6subjects
  1. Apr 23, 2021President

    Became Public Law No: 117-8.

  2. Apr 23, 2021BecameLaw36000

    Became Public Law No: 117-8.

  3. Apr 23, 2021President

    Signed by President.

  4. Apr 23, 2021BecameLaw36000

    Signed by President.

  5. Apr 20, 2021Floor

    Presented to President.

  6. Apr 20, 2021President28000

    Presented to President.

  7. Apr 14, 2021FloorH38310

    Motion to reconsider laid on the table Agreed to without objection.

  8. Apr 14, 2021FloorH37300

    On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 8 (Roll no. 101). (text: CR H1754)

  9. Apr 14, 2021Floor8000

    Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 8 (Roll no. 101).(text: CR H1754)

  10. Apr 14, 2021FloorH30000

    Considered as unfinished business. (consideration: CR H1783-1784)

  11. Apr 14, 2021FloorH37220

    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.

  12. Apr 14, 2021FloorH8D000

    DEBATE - The House proceeded with forty minutes of debate on S. 164.

  13. Apr 14, 2021FloorH30000

    Considered under suspension of the rules. (consideration: CR H1754-1755)

  14. Apr 14, 2021FloorH30300

    Mr. Pallone moved to suspend the rules and pass the bill.

  15. Mar 8, 2021FloorH15000

    Held at the desk.

  16. Mar 8, 2021FloorH14000

    Received in the House.

  17. Mar 8, 2021Floor

    Message on Senate action sent to the House.

  18. Mar 3, 2021Floor

    Passed Senate without amendment by Unanimous Consent. (text: CR S1021)

  19. Mar 3, 2021Floor17000

    Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S1021)

  20. Mar 3, 2021Discharge

    Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S1021)

    Health, Education, Labor, and Pensions Committee
  21. Mar 3, 2021Committee14500

    Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.(consideration: CR S1021)

    Health, Education, Labor, and Pensions Committee
  22. Feb 2, 2021IntroReferral

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Health, Education, Labor, and Pensions Committee
  23. Feb 2, 2021IntroReferral10000

    Introduced in Senate

Public LawApr 23, 202149

Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

Passed HouseApr 14, 202153

Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

Passed SenateMar 3, 202155

Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

Introduced in SenateFeb 2, 2021

Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

Advancing Education on Biosimilars Act of 2021 — Informed